{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-057689","form_type":"8-K","ticker":"TOVX","cik":"0000894158","company_name":"Theriva Biologics, Inc.","filed_at":"2024-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:22.346637+00:00","generated_at":"2026-06-02T21:29:58.149190+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Theriva Biologics reports $18.3M cash as of Q1 2024, VIRAGE enrollment on track for Q3 completion","bullets":["Cash and cash equivalents $18.3M at March 31, 2024, expected to fund operations into Q1 2025.","R&D expenses $3.5M in Q1 2024, up 16% YoY due to clinical trial costs.","VIRAGE Phase 2b trial for VCN-01 in metastatic PDAC expected to complete enrollment in Q3 2024.","Positive topline data from Phase 1 trial of VCN-01 in pediatric refractory retinoblastoma – study committee deemed results positive.","Licensing discussions ongoing for SYN-020 intestinal alkaline phosphatase asset."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-057689","json":"https://secwatch.observer/filing/0001104659-24-057689.json","markdown":"https://secwatch.observer/filing/0001104659-24-057689.md","text":"https://secwatch.observer/filing/0001104659-24-057689.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/894158/000110465924057689/0001104659-24-057689-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/894158/000110465924057689/tm2413496d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T21:29:58.149190+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2ed7db578632d6d58226dd559e8aa6939bc7aca9","claim":"Theriva Biologics, Inc. reported financial results for first quarter ended March 31, 2024.","evidence_excerpt":"On May 7, 2024, Theriva Biologics, Inc., a Nevada corporation (the “Registrant”) issued a press release that included financial information for its quarter ended March 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/894158/000110465924057689/0001104659-24-057689-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Result","value":"reported results"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}